Silk Road Medical

Silk Road Medical (NSDQ:SILK) this week posted third-quarter results that beat the overall consensus on Wall Street.

The Sunnyvale, California-based stroke treatment tech company reported net losses of $10.3 million, or -29¢ per share, on sales of $37.4 million for the three months ended Sept. 30, on sales growth of 51.31% and profit gain from net losses of $13.9 million in Q3 2021.

Earnings per share were 14¢ ahead of The Street, where analysts were looking for sales of $33.64 million.

“Our performance in the third quarter reflects broad-based U.S. TCAR strength as we capitalize on the operational infrastructure our team has worked so hard to establish,” CEO Erica Rogers said in a news release. “This is the first time in over seven decades that the carotid artery disease market has experienced a level playing field for a minimally invasive approach with open surgery. With TCAR now available to all eligible patients, we have cemented the foundation to es…

Silk Road Medical (NSDQ:SILK) announced that it commenced a proposed underwritten public offering of $100 million in common stock.

The Sunnyvale, California–based stroke treatment tech company plans to use proceeds to expand its sales force and operations. It also intends to increase its R&D activities, conduct or sponsor clinical trials and lease new facilities. Silk Road wants to expand internationally, too, while additional funds may go toward working capital and other corporate purposes.

Silk Road said in a news release that it plans to grant underwriters a 30-day option to purchase additional shares. That option allows underwriters to purchase common stock in an amount of up to 15% of the number of shares sold in the offering.

The company said the offering is subject to market and other conditions. It offered no assurance as to whether it may complete the offering and no guarantee of the actual size or terms of it.

Silk Road said it also …

Silk Road Medical (NSDQ:SILK) this week posted first-quarter results that beat the revenue consensus on Wall Street and missed on earnings.

The Sunnyvale, California-based stroke treatment tech company reported losses of $16.7 million, or -48¢ per share, on sales of $28.02 million for the three months ended March 31 for sales growth of 27% compared with Q1 2021.

Earnings per share were 11¢ behind The Street, where analysts were looking for sales of $28.02 million.

“We demonstrated strong execution in the first quarter and remain confident in our ability to drive further TCAR adoption, supplemented by our recent FDA approved label expansion for our stent to include standard surgical risk patients,” CEO Erica Rogers said in a news release. “This approval levels a playing field once dominated by open surgery, allowing an expanded patient population to benefit from our less invasive approach as we establish TCAR as the new standard of care in stroke preventi…

Silk Road Medical (NSDQ:SILK) this week posted fourth-quarter results that beat the revenue consensus on Wall Street and missed on earnings estimates.

The Sunnyvale, California-based stroke treatment company reported losses of -$14.7 million, or -42¢ per share, on sales of $28.3 million for the three months ended Dec. 31, 2021, for a bottom-line gain of 12.3% on sales growth of 33.75% compared with Q4 2020.

Earnings per share were 42¢, 7¢ behind The Street, where analysts were looking for sales of $25.91 million.

“Our team and physicians had a tremendous impact in 2021, performing nearly 14,000 cases and driving record annual revenue of $101.5 million,” president and CEO Erica Rogers said in a news release. “We drove measurable progress on regulatory and clinical fronts in anticipation of standard surgical risk approval in the U.S., entry into Japan and China, and development of our long-term pipeline, and we are well-positioned to continue establishing …